The Inflammatory CXC Chemokines, GROα^high, IP-10^low, and MIG^low, in Tumor Microenvironment Can Be Used as New Indicators for Non-small Cell Lung Cancer Progression

References

• Addison CL, Arenberg DA, Morris SB, et al. 2000. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther, 11(2), 247–261. doi:10.1089/10430340050015996
   PubMed Web of Science ®Google Scholar
• Arenberg DA, Kunkel SL, Polverini PJ, et al. 1996a. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest, 97(12), 2792–2802. doi:10.1172/jci118734
   PubMed Web of Science ®Google Scholar
• Arenberg DA, Kunkel SL, Polverini PJ, et al. 1996b. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med, 184(3), 981–992.
   PubMed Web of Science ®Google Scholar
• Asarat M, Vasiljevic T, Apostolopoulos V, et al. 2015. Short-chain fatty acids regulate secretion of IL-8 from human intestinal epithelial cell lines in vitro. Immunol Invest, 44(7), 678–693. doi:10.3109/08820139.2015.1085389
   PubMed Web of Science ®Google Scholar
• Bhat IA, Qasim I, Masoodi KZ, et al. 2015. Significant impact of IL-6-174G/C but inverse relation with -634 C/G polymorphism in patients with non-small cell lung cancer in Kashmiri population. Immunol Invest, 44(4), 349–360. doi:10.3109/08820139.2015.1004336
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zeng H, et al. 2015. Annual report on status of cancer in China, 2011. Chin J Cancer Res, 27(1), 2–12. doi:10.3978/j.issn.1000-9604.2015.01.06
   PubMed Web of Science ®Google Scholar
• Coperchini F, Pignatti P, Leporati P, et al. 2016. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-alpha-induced CXCL8 secretion. Endocrine, 54(1), 123–128. doi:10.1007/s12020-015-0764-x
   PubMed Web of Science ®Google Scholar
• Haghnegahdar H, Du J, Wang D, et al. 2000. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol, 67(1), 53–62.
   Google Scholar
• Kojima H, Shijubo N, and Abe S. 2002. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer, 94(4), 1083–1093.
   Google Scholar
• Lunardi S, Jamieson NB, Lim SY, et al. 2014. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget, 5(22), 11064–11080. doi:10.18632/oncotarget.2519
   PubMed Web of Science ®Google Scholar
• Lv M, Xu Y, Tang R, et al. 2014. miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancer. Mol Cancer Ther, 13(12), 3152–3162. doi:10.1158/1535-7163.mct-14-0448
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. 2000. The biology of chemokines and their receptors. Annu Rev Immunol, 18, 217–242. doi:10.1146/annurev.immunol.18.1.217
   PubMed Web of Science ®Google Scholar
• Rotondi M, Coperchini F, Chiovato L. 2013. CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice. Cytokine Growth Factor Rev, 24(6), 539–546. doi:10.1016/j.cytogfr.2013.08.001
   PubMed Web of Science ®Google Scholar
• Ruehlmann JM, Xiang R, Niethammer AG, et al. 2001. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res, 61(23), 8498–8503.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Belperio JA, Burdick MD, et al. 2004. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci, 1028, 351–360. doi:10.1196/annals.1322.041
   PubMed Web of Science ®Google Scholar
• Strieter RM, Burdick MD, Mestas J, et al. 2006. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer, 42(6), 768–778. doi:10.1016/j.ejca.2006.01.006
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. 2015. Global cancer statistics, 2012. CA Cancer J Clin, 65(2), 87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• White ES, Flaherty KR, Carskadon S, et al. 2003. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res, 9(2), 853–860.
   Google Scholar
• Wu Z, Huang X, Han X, et al. 2016. The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients. Biomed Pharmacother, 78, 8–13. doi:10.1016/j.biopha.2015.12.021
   Google Scholar
• Yates-Binder CC, Rodgers M, Jaynes J, et al. 2012. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis. PLoS One, 7(7), e40812. doi:10.1371/journal.pone.0040812
   PubMed Web of Science ®Google Scholar
• Yuan A, Yang PC, Yu CJ, et al. 2000. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med, 162(5), 1957–1963. doi:10.1164/ajrccm.162.5.2002108
   PubMed Web of Science ®Google Scholar
• Zhang R, Tian L, Chen LJ, et al. 2006. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther, 13(17), 1263–1271. doi:10.1038/sj.gt.3302756
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. 2000. Chemokines: a new classification system and their role in immunity. Immunity, 12(2),121–127.
   Google Scholar
• Zlotnik A, Yoshie O. 2012. The chemokine superfamily revisited. Immunity, 36(5), 705–716. doi:10.1016/j.immuni.2012.05.008
   PubMed Web of Science ®Google Scholar